

Rule 3.19A.2

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity Antisense Therapeutics Limited (ASX: ANP)</b>
<b>ABN 41 095 060 745</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mark Diamond
<b>Date of last notice</b>	03 December 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct		
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-		
<b>Date of change</b>	22 December 2021		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	4,423,173	14,000,000
	<b>Indirect</b>	-	-
	<b>Total</b>	<b>4,423,173</b>	<b>14,000,000</b>
<b>Class</b>	a) Fully Paid Ordinary Shares b) Unlisted Options		
<b>Number acquired</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	470,549	235,274
	<b>Indirect</b>	-	-
	<b>Total</b>	<b>470,549</b>	<b>235,274</b>
<b>Number disposed</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	-	-
	<b>Indirect</b>	-	-
	<b>Total</b>	-	-

## Appendix 3Y Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$112,931.76													
<b>No. of securities held after change</b>	<table border="1"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>4,893,722</td> <td>14,235,274</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>4,893,722</b></td> <td><b>14,235,274</b></td> </tr> </tbody> </table>			Shares	Options	<b>Direct</b>	4,893,722	14,235,274	<b>Indirect</b>	-	-	<b>Total</b>	<b>4,893,722</b>	<b>14,235,274</b>
	Shares	Options												
<b>Direct</b>	4,893,722	14,235,274												
<b>Indirect</b>	-	-												
<b>Total</b>	<b>4,893,722</b>	<b>14,235,274</b>												
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a & b) Issue of shares and free-attaching options as per Entitlement Offer													

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A



22 December 2021